A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Molnupiravir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MOVe-AHEAD
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 08 Sep 2023 Results published in the Journal of Infection
- 21 Feb 2023 According to a Merck & Co media release, the company intends to submit full results from this study for presentation at a scientific meeting or for publication.
- 21 Feb 2023 Primary endpoint (Percentage of participants who have undetectable SARS-CoV-2 in baseline nasopharyngeal (NP) swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 [ Time Frame: Up to Day 14 ]) has not been met, according to a Merck & Co media release.